ArticleThe Pediatric infectious disease journal2019
Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.
Nazario D Rivera-Chaparro, Jessica Ericson, Huali Wu, P Brian Smith, Reese H Clark, Daniel K Benjamin, Michael Cohen-Wolkowiez, Rachel G Greenberg
Open access · greenAbstract readEvaluation Study
In one paragraphArticle in The Pediatric infectious disease journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors at 4 institutions in 1 country.
Nazario D Rivera-ChaparroFrom the Duke Clinical Research Institute.
Jessica EricsonDepartment of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania.
Huali WuFrom the Duke Clinical Research Institute.
P Brian SmithFrom the Duke Clinical Research Institute.
Reese H ClarkPediatrix Medical Group, Inc., Sunrise, Florida.
Daniel K BenjaminFrom the Duke Clinical Research Institute.
Michael Cohen-WolkowiezFrom the Duke Clinical Research Institute.
Rachel G GreenbergFrom the Duke Clinical Research Institute.
Clinical Research Institute · USDuke University · USPenn State Milton S. Hershey Medical Center · USSunrise Medical (United States) · US
Funding
Project-005U2COD023375 · OD · DUKE UNIVERSITY · PI Linda S Adair, Phillip Brian Smith · 2016 to 2026
$215.9MCOVID-19 Supplement - Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT)U24TR001608 · NCATS · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K., HERNANDEZ, ADRIAN · 2016 to 2022
$177.0MDuke CTSA (Composite)UL1TR001117 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, LI, JENNIFER S · 2013 to 2017
$41.3MPenn State Clinical and Translational Science InstituteUL1TR002014 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI KRASCHNEWSKI, JENNIFER L. · 2016 to 2025
$33.7MUNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5MPenn State Institutional Career Development CoreKL2TR002015 · NCATS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI VAN SCOY, LAUREN JODI · 2016 to 2025
$7.8MPhysiologically-Based Pharmacokinetic Models for Optimal Drug Dosing in ChildrenR01HD076676 · NICHD · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2014 to 2017
$2.6MMentorship of early-career pediatricians in quantitiative methods and therapeuticK24HD058735 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2009 to 2018
$1.5MPATIENT SAFETY RESEARCH DURING NEONATAL CARE (R21)R21HD080606 · NICHD · DUKE UNIVERSITY · PI SMITH, PHILLIP BRIAN · 2015 to 2016
$457kNCATS NIH HHS KL2 TR002015NCATS NIH HHS U24 TR001608NCATS NIH HHS UL1 TR001117NCATS NIH HHS UL1 TR002014NICHD NIH HHS K24 HD058735NICHD NIH HHS R01 HD076676NICHD NIH HHS R21 HD080606NIGMS NIH HHS T32 GM086330
6 · The paper itselfAbstract
Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.
Indexed as
Electronic Health RecordsAntifungal AgentsCandidiasisFemaleHospitalizationHumansInfantMaleMicafunginAntifungal AgentsMicafungin
Identifiers
PMID29601453
PMCPMC6163100
OpenAlexW2794472136
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390